London Daily

Focus on the big picture.
Sunday, Jun 01, 2025

Moderna chief predicts existing vaccines will struggle with Omicron

Moderna chief predicts existing vaccines will struggle with Omicron

The chief executive of Moderna has predicted that existing vaccines will be much less effective at tackling Omicron than earlier strains of coronavirus and warned it would take months before pharmaceutical companies could manufacture new variant-specific jabs at scale.
Stéphane Bancel said the high number of Omicron mutations on the spike protein, which the virus uses to infect human cells, and the rapid spread of the variant in South Africa suggested that the current crop of vaccines may need to be modified next year.

“There is no world, I think, where [the effectiveness] is the same level . . . we had with [the] Delta [variant],” Bancel told the Financial Times in an interview at the company’s headquarters in Cambridge, Massachusetts.

He added: “I think it’s going to be a material drop. I just don’t know how much because we need to wait for the data. But all the scientists I’ve talked to . . . are like, ‘This is not going to be good’.”

The Moderna chief executive’s comments come as public health experts and politicians have tried to strike a more upbeat tone about existing vaccines’ capacity to confer protection against Omicron.

On Monday, Scott Gottlieb, a director of Pfizer and former commissioner of the US Food and Drug Administration, told CNBC: “There’s a reasonable degree of confidence in vaccine circles that [with] at least three doses . . . the patient is going to have fairly good protection against this variant.”

Joe Biden, US president, subsequently said Omicron was “a cause for concern, not a cause for panic,” adding that the government’s medical experts “believe that the vaccines will continue to provide a degree of protection against severe disease”.

However, Bancel said scientists were worried because 32 of the 50 mutations in the Omicron variant are on the spike protein, which current vaccines focus on to boost the human body’s immune system to combat Covid.

Most experts thought such a highly mutated variant would not emerge for another year or two, Bancel added.

The Moderna chief’s predictions rattled investors in Europe and Asia on Tuesday, with equities and crude prices dropping. The European Stoxx 600 share index fell around 1.3 per cent with the UK’s FTSE 100, Germany’s Dax and France’s Cac 40 all down by around the same margin. Hong Kong’s Hang Seng index was 2.3 per cent lower.

Mansoor Mohi-uddin, chief economist at the Bank of Singapore, said that while investors were not pricing in a more serious disruption to the global economy from Omicron, it could take weeks for a clearer picture to emerge. “The view is still that it’s going to be a temporary hit, rather like [the Delta variant] turned out to be.”

Moderna and Pfizer have become the vaccine suppliers of choice for most of the developed world due to the high effectiveness of their jabs, which are based on messenger RNA (mRNA) technology.

In August, Moderna announced that people vaccinated with two doses of its jab “maintained antibodies through six months, including against variants of concern such as the Delta variant”.

But studies suggested that the company’s vaccine was less effective at preventing outbreaks of Delta than earlier strains of the virus.

A Stanford University study of a Delta outbreak at a California prison published last month found that Moderna’s jab was 56.6 per cent effective against infection — substantially lower than the level in studies conducted before the emergence of the variant, the researchers said.

Moderna and Pfizer are now working on new vaccines to target the Omicron variant, which the World Health Organization has said poses a “very high risk”.

Bancel said data indicating how existing vaccines performed against the Omicron variant, and whether it caused severe disease, should become available within two weeks.

But he said it would take several months before an Omicron-specific vaccine could be produced at scale, and suggested there might be a case for giving more potent boosters to the elderly or people with compromised immune systems in the meantime.

“[Moderna] and Pfizer cannot get a billion doses next week. The maths doesn’t work. But could we get the billion doses out by the summer? Sure,” said Bancel, who predicted Moderna could make a total of 2bn-3bn doses in 2022.

But he said it would be risky to shift Moderna’s entire production capacity to an Omicron-targeted jab at a time when other variants were still in circulation.

Bancel also hit out at critics who have accused vaccine makers of not doing enough to support rollouts in developing countries such as South Africa, where only a quarter of the population is fully inoculated, according to Johns Hopkins University.

“This was mostly a policy decision by the rich countries. In the US, we were told we had no choice but to give 60 per cent of our output to the US government. That was not a Moderna decision, that was a US government decision,” he said.

Bancel also said there was a surplus of jabs earmarked for Africa and that 70m Moderna vaccines were sitting in warehouses because Covax, an international body tasked with supplying low-income nations, or individual governments had not taken delivery of them.

“We are running out of space,” he said. “It’s because either they don’t have customs documents, or they don’t have fridge space, or because the ability to get doses in arms is a challenge.”
Newsletter

Related Articles

0:00
0:00
Close
Hegseth Warns of Potential Chinese Military Action Against Taiwan
OPEC+ Agrees to Increase Oil Output for Third Consecutive Month
Jamie Dimon Warns U.S. Bond Market Faces Pressure from Rising Debt
Turkey Detains Istanbul Officials Amid Anti-Corruption Crackdown
Taylor Swift Gains Ownership of Her First Six Albums
Bangkok Ranked World's Top City for Remote Work in 2025
Satirical Sketch Sparks Political Spouse Feud in South Korea
Indonesia Quarry Collapse Leaves Multiple Dead and Missing
South Korean Election Video Pulled Amid Misogyny Outcry
Asian Economies Shift Away from US Dollar Amid Trade Tensions
Netflix Investigates Allegations of On-Set Mistreatment in K-Drama Production
US Defence Chief Reaffirms Strong Ties with Singapore Amid Regional Tensions
Vietnam Faces Strategic Dilemma Over China's Mekong River Projects
Malaysia's First AI Preacher Sparks Debate on Islamic Principles
White House Press Secretary Criticizes Harvard Funding, Advocates for Vocational Training
France to Implement Nationwide Smoking Ban in Outdoor Spaces Frequented by Children
Meta and Anduril Collaborate on AI-Driven Military Augmented Reality Systems
Russia's Fossil Fuel Revenues Approach €900 Billion Since Ukraine Invasion
U.S. Justice Department Reduces American Bar Association's Role in Judicial Nominations
U.S. Department of Energy Unveils 'Doudna' Supercomputer to Advance AI Research
U.S. SEC Dismisses Lawsuit Against Binance Amid Regulatory Shift
Alcohol Industry Faces Increased Scrutiny Amid Health Concerns
Italy Faces Population Decline Amid Youth Emigration
U.S. Goods Imports Plunge Nearly 20% Amid Tariff Disruptions
OpenAI Faces Competition from Cheaper AI Rivals
Foreign Tax Provision in U.S. Budget Bill Alarms Investors
Trump Accuses China of Violating Trade Agreement
Gerry Adams Wins Libel Case Against BBC
Russia Accuses Serbia of Supplying Arms to Ukraine
EU Central Bank Pushes to Replace US Dollar with Euro as World’s Main Currency
Chinese Woman Dies After Being Forced to Visit Bank Despite Critical Illness
President Trump Grants Full Pardons to Reality TV Stars Todd and Julie Chrisley
Texas Enacts App Store Accountability Act Mandating Age Verification
U.S. Health Secretary Ends Select COVID-19 Vaccine Recommendations
Vatican Calls for Sustainable Tourism in 2025 Message
Trump Warns Putin Is 'Playing with Fire' Amid Escalating Ukraine Conflict
India and Pakistan Engage Trump-Linked Lobbyists to Influence U.S. Policy
U.S. Halts New Student Visa Interviews Amid Enhanced Security Measures
Trump Administration Cancels $100 Million in Federal Contracts with Harvard
SpaceX Starship Test Flight Ends in Failure, Mars Mission Timeline Uncertain
King Charles Affirms Canadian Sovereignty Amid U.S. Statehood Pressure
Trump Threatens 25% Tariff on iPhones Amid Dispute with Apple CEO
Putin's Helicopter Reportedly Targeted by Ukrainian Drones
Liverpool Car Ramming Incident Leaves Multiple Injured
Australia Faces Immigration Debate Following Labor Party Victory
Iranian Revolutionary Guard Founder Warns Against Trusting Regime in Nuclear Talks
Macron Dismisses Viral Video of Wife's Gesture as Playful Banter
Cleveland Clinic Study Questions Effectiveness of Recent Flu Vaccine
Netanyahu Accuses Starmer of Siding with Hamas
Junior Doctors Threaten Strike Over 4% Pay Offer
×